Physician profile
Amanda Whitehead
NPI 1578806931
$1,213.57
in general payments reported to CMS, 2019-2025
14 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $242 · 2023: $196 · 2024: $146 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $394.93 | 2021-2023 | Infinity |
| Galderma Laboratories, L.P. | $281.26 | 2021-2024 | |
| Medtronic, INC. | $169.60 | 2021-2022 | |
| Si-Bone, INC. | $143.10 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $44.19 | 2023-2024 | Bridion |
| Averitas Pharma INC. | $27.12 | 2025 | Qutenza |
| Sumitomo Pharma America, INC. | $26.68 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $24.94 | 2024 | Saphnelo |
| Indivior INC. | $23.74 | 2025 | Sublocade |
| Novo Nordisk INC | $19.55 | 2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.79 | 2024 | Jardiance |
| Boston Scientific Corporation | $17.28 | 2023 | |
| Collegium Pharmaceutical, INC. | $14.03 | 2025 | Belbuca |
| Foundation Fusion Solutions, LLC | $8.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.